BioLife Solutions Q4 2022 Earnings Report

BioLife Solutions EPS Results

• Actual EPS: -$0.19
• Consensus EPS: -$0.16
• Beat/Miss: Missed by -$0.03
• One Year Ago EPS: N/A

BioLife Solutions Revenue Results

• Actual Revenue: $44.26 million
• Expected Revenue: $43.34 million
• Beat/Miss: Beat by +$920.00 thousand
• YoY Revenue Growth: N/A

BioLife Solutions Announcement Details

• Quarter: Q4 2022
• Date: 3/16/2023
• Time: N/A

BioLife Solutions (NASDAQ:BLFS) develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.